View Cart  

CLINICAL TRIALS IN LOW-COST COUNTRIES OFFER BIG SAVINGS, GSK SAYS

A A

Moving human clinical trials to low-cost countries could save GlaxoSmithKline (GSK) more than $200 million annually in R&D costs, according to the drug giant’s top executive.

To View This Article:

Login

Subscribe To Drug Industry Daily